Clinical Trial Update: Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating HSK39297 in anti-C5–treated patients with paroxysmal nocturnal haemoglobinuria and anemia has completed to assess efficacy and safety…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Haemoglobinuria

Drugs mentioned

• HSK39297

Snippet

Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Conditions: Paroxysmal Nocturnal Haemoglobinuria (PNH) | Phase 3 | Status: COMPLETED